Overview of biological and clinical data referring to patients in the HOVON, TCGA and GSE106291 datasets
| . | HOVON . | TCGA . | GSE106291 . |
|---|---|---|---|
| Sex | |||
| Female | 294 | 56 | 129 |
| Male | 315 | 67 | 119 |
| Fab | |||
| AML with unknown FAB subtype | 1 | 0 | NA |
| M0 | 26 | 12 | NA |
| M1 | 134 | 38 | NA |
| M2 | 154 | 28 | NA |
| M4 | 111 | 29 | NA |
| M5 | 139 | 12 | NA |
| M6 | 9 | 2 | NA |
| M7 | 0 | 1 | NA |
| RAEB | 5 | 0 | NA |
| RAEB-t | 19 | 0 | NA |
| Unknown | 11 | 1 | NA |
| BM blasts abundance at diagnosis | |||
| Median blasts (%) | 67 (0-98) | 74 (30-100) | 73 (6-100) |
| Cytogenetic risk | |||
| Adverse | 123 | 26 | NA |
| Favorable | 204 | 17 | NA |
| Intermediate | 280 | 78 | NA |
| Not evaluable risk | 2 | 2 | NA |
| Treatment | |||
| Allogeneic HSCT | 196 | 64 | NA |
| Autologous HSCT | 91 | 6 | NA |
| Chemotherapy | 320 | 53 | NA |
| Unknown | 2 | 0 | NA |
| . | HOVON . | TCGA . | GSE106291 . |
|---|---|---|---|
| Sex | |||
| Female | 294 | 56 | 129 |
| Male | 315 | 67 | 119 |
| Fab | |||
| AML with unknown FAB subtype | 1 | 0 | NA |
| M0 | 26 | 12 | NA |
| M1 | 134 | 38 | NA |
| M2 | 154 | 28 | NA |
| M4 | 111 | 29 | NA |
| M5 | 139 | 12 | NA |
| M6 | 9 | 2 | NA |
| M7 | 0 | 1 | NA |
| RAEB | 5 | 0 | NA |
| RAEB-t | 19 | 0 | NA |
| Unknown | 11 | 1 | NA |
| BM blasts abundance at diagnosis | |||
| Median blasts (%) | 67 (0-98) | 74 (30-100) | 73 (6-100) |
| Cytogenetic risk | |||
| Adverse | 123 | 26 | NA |
| Favorable | 204 | 17 | NA |
| Intermediate | 280 | 78 | NA |
| Not evaluable risk | 2 | 2 | NA |
| Treatment | |||
| Allogeneic HSCT | 196 | 64 | NA |
| Autologous HSCT | 91 | 6 | NA |
| Chemotherapy | 320 | 53 | NA |
| Unknown | 2 | 0 | NA |
NA, not available.